Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Public ClinicalTrials.gov record NCT04486833. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT04486833
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Genprex, Inc.
- Industry
- Enrollment
- 158 participants
Conditions and interventions
Conditions
Interventions
- quaratusugene ozeplasmid Biological
- osimertinib Drug
- Platinum-Based Chemotherapy Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2, 2021
- Primary completion
- Feb 29, 2028
- Completion
- Feb 28, 2029
- Last update posted
- Jan 20, 2026
2021 – 2029
United States locations
- U.S. sites
- 10
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Valkyrie Clinical Trials | Los Angeles | California | 90067 | Recruiting |
| Rocky Mountain Cancer Centers | Lone Tree | Colorado | 80124 | Recruiting |
| Carle Cancer Institute | Urbana | Illinois | 61801 | Recruiting |
| Markey Cancer Center | Lexington | Kentucky | 40536 | Recruiting |
| Maryland Oncology Hematology | Rockville | Maryland | 20850 | Recruiting |
| The Valley Hospital - Luckow Pavilion | Paramus | New Jersey | 07652 | Recruiting |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | Recruiting |
| Millennium Oncology | Houston | Texas | 77090 | Terminated |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | Recruiting |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04486833, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 20, 2026 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04486833 live on ClinicalTrials.gov.